The global cell therapy manufacturing market is poised for remarkable growth, with an expected valuation of USD 4,134.48 million in 2023, anticipated to reach approximately USD 15,634.67 million by the end of 2033. This growth signifies a compound annual growth rate (CAGR) of 14.2% throughout the forecast period.
Leading the market, autologous cell therapy manufacturing accounted for about 56.0% of the market share in 2021. These therapies, which utilize a patient’s own cells for treatment, are increasingly recognized for their effectiveness in addressing various medical conditions, including cancer and genetic disorders.
Modern cell therapies include sophisticated gene-edited products such as chimeric antigen receptor (CAR)-T cells and innovative tissue engineering products like Holoclar. These advancements go beyond traditional blood transfusions and hematopoietic progenitor stem cell transplantation, demonstrating the evolving landscape of cell-based therapies.
The quality standards in cell therapy manufacturing have seen significant advancements in response to the need for consistency, reliability, and efficacy in therapeutic products. Enhanced manufacturing processes ensure that these therapies meet rigorous quality requirements, ultimately improving patient outcomes.
Key Market Drivers:
- Growing demand for autologous cell therapies: The effectiveness and personalization of autologous treatments are driving their increased adoption in clinical settings.
- Innovations in cell-based products: Continuous advancements in gene editing and tissue engineering are expanding the range of available therapies.
- Improved quality standards: The evolution of manufacturing processes is enhancing product consistency and therapeutic efficacy.
As the healthcare industry embraces innovative cell-based treatments, the global cell therapy manufacturing market is set to experience substantial growth, providing patients with effective and personalized therapeutic options.
Cell therapies are utilized widely to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. Introduction of reagents and closed system automated equipment for the manufacturing of cellular therapies is an outcome of the increasing research activities in the field of such therapies.
A decentralized manufacturing model for clinical trials in cell therapies engaging multiple sites are being favored across the globe. Such instances advocate the treatment of patients using cells, which are produced by utilizing automated equipment at each participating center by considering a single, centrally held investigational new drug application (IND).
Many academic centres are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi- centres Clinical Trials. The global cell therapy manufacturing market would thus observe a boom in the next decade. Besides, introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approach would further propel the overall growth in the market during the projected period.
Key Takeaways from Market Study
- By source, the autologous segment held a global market share of about 0%in 2021.
- Based on indication, the cancer segment held nearly 0%in 2021 in the cell therapy manufacturing market.
- In terms of purpose, the clinical segment accounted for around 0%of the global market share in 2021.
- Injectable route of administration of cell therapies generated a global market share of around 0%in 2021.
- By cell type, the hematopoietic stem cells (HSC) segment held a share of around 0%in the global cell therapy manufacturing market in 2021.
- By end use, the hospital settings category generated a share of around 1%in 2021 in the global cell therapy manufacturing market.
- China held a share of around 2%in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.
Competitive Landscape: Cell Therapy Manufacturing Market
Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify transition from clinical development to commercial manufacturing among Cell Therapy Developers.
- Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Get Exclusive Insights on Cell Therapy Manufacturing Market
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Key Players:
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIQ
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Key Segments Covered in Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
